Aurobindo Pharma


'Aurobindo Pharma' - 15 Video Result(s)

'Aurobindo Pharma' - 284 News Result(s)

  • Buy Tata Power, BHEL; Sell HCL Tech: Sumeet Jain

    Buy Tata Power, BHEL; Sell HCL Tech: Sumeet Jain

    The Nifty faces stiff resistance around 8,600-8,620 and fresh buying is unlikely to emerge unless the benchmark takes out these levels, says Sumeet Jain, head - derivatives & technicals with Destimoney Securities. Nifty is likely to see expiry below 8,450 for this month's contract, he added.

  • Sensex Ends Over 100 Points Higher On Buying In Pharma Shares

    Sensex Ends Over 100 Points Higher On Buying In Pharma Shares

    Indian shares rose on Wednesday on the back of broad-based buying while pharma stocks outperformed as drug makers such as Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the U.S.

  • Aurobindo Pharma Surges 4% On US Approval For Cholesterol Drug

    Aurobindo Pharma Surges 4% On US Approval For Cholesterol Drug

    Aurobindo Pharma surged nearly 4 per cent to Rs 788 today after the drugmaker launched the Rosuvastatin Calcium Tablets in the US following approval from the American drug regulator.

  • Sensex Rises Over 100 Points Led By Gains In HDFC Bank, ITC

    Sensex Rises Over 100 Points Led By Gains In HDFC Bank, ITC

    The BSE Sensex rose over 100 points on Wednesday, while the broader Nifty traded above the key 8,550 levels. Indian stock markets outperformed Asian equities that traded with a mixed bias today.

  • Pharma Companies May Report Strong Revenue Growth For Q1: Jefferies

    Pharma Companies May Report Strong Revenue Growth For Q1: Jefferies

    The pharmaceuticals sector may report strong revenue growth for the first quarter of the current fiscal year, foreign brokerage Jefferies has said in a report.

  • Buy Reliance Infra, Sell Aurobindo Pharma: Jay Thakkar

    Buy Reliance Infra, Sell Aurobindo Pharma: Jay Thakkar

    Nifty is trading in a range between 8,250-8,400 and it is difficult to say which way the Nifty will breakout. Once it breaks out on either side it would be prudent take a positional call and at current juncture index trading should be avoided, says Jay Thakkar, senior technical analyst with Sharekhan.

  • Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool

    Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool

    Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.

  • Buy Reliance Infra, Aurobindo Pharma; Avoid Ashok Leyland: Sumeet Bagadia

    Buy Reliance Infra, Aurobindo Pharma; Avoid Ashok Leyland: Sumeet Bagadia

    Nifty faces resistance around levels of 8,400 and till the time 8,400 is not taken out, Nifty can see a correction up to levels of 8,300-8,280, says Sumeet Bagadia, associate director at Choice Broking. Correction should be used as a buying opportunity in Nifty with stop loss around 8,270-8,280 for target of 8,400, added Mr Bagadia.

  • Pharma Stocks Outperform; Lupin, Sun Pharma Rise 2%

    Pharma Stocks Outperform; Lupin, Sun Pharma Rise 2%

    Shares of pharmaceutical companies such as Lupin, Sun Pharmaceuticals, Dr Reddy's Laboratories and Aurobindo Pharma outperformed today in an otherwise subdued market.

  • Every Dip Buying Opportunity, Go Long In GAIL India, IGL: Ruchit Jain

    Every Dip Buying Opportunity, Go Long In GAIL India, IGL: Ruchit Jain

    Buying in Nifty on Wednesday emerged once it went closer to its support zone of 8,060 which suggest that there are no reversal signs and indicates that Nifty would not correct significantly from current levels, says Ruchit Jain, equity technical analyst with Angel Broking.

  • Investment Board Refers Holcim Proposal To Cabinet For Approval

    Investment Board Refers Holcim Proposal To Cabinet For Approval

    Inter-ministerial body FIPB has referred the Rs 3,400-crore foreign investment proposal of Holcim (India) to the Cabinet Committee on Economic Affairs for approval, while deferred the decision on Vodafone's application for acquisition of You Broadband India.

  • Buy Jet Airways, ONGC; Avoid Aurobindo Pharma: Ruchit Jain

    Buy Jet Airways, ONGC; Avoid Aurobindo Pharma: Ruchit Jain

    Nifty is trading near important technical levels and it is better to book profits on the positions taken at lower levels rather than going long, says Ruchit Jain, equity technical analyst with Angel Broking.

  • Aurobindo Pharma Fourth Quarter Profit Jumps 40%; Shares Rise 4%

    Aurobindo Pharma Fourth Quarter Profit Jumps 40%; Shares Rise 4%

    Aurobindo Pharma Ltd, India's fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 per cent, above estimates, sending shares up as much as 4 per cent.

  • Aurobindo Pharma Posts Profit Of Rs 563 Crore In Q4

    Aurobindo Pharma Posts Profit Of Rs 563 Crore In Q4

    Drug maker Aurobindo Pharma on Monday posted a consolidated net profit of Rs 562.85 crore for the fiscal fourth quarter that ended on March 31, 2016.

  • Cabinet To Decide On Axis Bank Rs 12,973 Crore Foreign Investment Proposal

    Cabinet To Decide On Axis Bank Rs 12,973 Crore Foreign Investment Proposal

    The Cabinet Committee on Economic Affairs will take a final call on Axis Bank's Rs 12,973-crore foreign investment proposal, the Finance Ministry said on Wednesday.

................................ Advertisement ................................

................................ Advertisement ................................